Q-omics provides the consensus-scored ARHGAP19-SLIT1 profile across patient tissues and cancer cell-line models. ARHGAP19-SLIT1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARHGAP19-SLIT1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ARHGAP19-SLIT1 RNA expression shows 11,828 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where ARHGAP19-SLIT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP19-SLIT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP19-SLIT1 survival associations across molecular data types. ARHGAP19-SLIT1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP19-SLIT1 RNA expression–survival associations across cancer types. High ARHGAP19-SLIT1 expression shows unfavorable associations in UVM, ACC, ESCA, UCEC and MESO, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARHGAP19-SLIT1 RNA expression.
This table summarizes ARHGAP19-SLIT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGAP19-SLIT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP19-SLIT1 shows lower tumor expression in COAD and higher tumor expression in THCA, PRAD, BRCA, BLCA and KIRC. The THCA box plot shows higher ARHGAP19-SLIT1 RNA expression in tumor versus normal tissue (log2 FC = +0.242, t-test p < 0.001).
This table shows molecular features associated with ARHGAP19-SLIT1 in patient tissues and cancer cell lines. In patient samples, ARHGAP19-SLIT1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP19-SLIT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
